Table of Contents
TABLE OF CONTENTS
LIST OF EXHIBITS
EXECUTIVE SUMMARY
METHODOLOGY
1.0 AD OVERVIEW
- 1.1 Definition of AD
- 1.1.1 Symptoms
- 1.1.2 Diagnosis
- 1.2 Segmentation of AD
- 1.3 Prevalence of AD
- 1.4 Unmet Need s in AD
- 1.5 Market Analyses Assumptions
- 1.5.1 Generic Competition
- 1.5.2 UK Forecasts
- 1.5.3 Mild to Moderate Market Assumptions
- 1.5.4 Moderate to Severe Market Assumptions
- 1.6 Market Analyses
- 1.6.1 US Market Forecast
- 1.6.2 European Market Forecast
- 1.6.3 Japanese Market Forecast
- 1.7 Competitive Analysis
- 1.8 Drugs That Address Associated Conditions
- 1.9 AD Research and Development
- 1.9.1 ACh Modulators
- 1.9.2 Neuroprotective and Neurotrophic Drugs
- 1.9.3 Beta-Amyloid Modulators
- 1.9.4 Beta-Secreta se Inhibitors
- 1.9.5 Other Compounds Under Development for AD
- 1.9.6 Application of Existing Products to AD
- 1.9.7 Innovative Approaches
2.0 AD PATIENT POPULATION
- 2.1 Definition of AD
- 2.1.1 Epidemiology
- 2.1.1.1 Clinical In vestiga tion s
- 2.1.2 Sym p tom s
- 2.1.3 Diagnosis
- 2.1.3.1 Psych ological Testin g
- 2.2 Segmentation of AD.
- 2.2.1 Mild to Moderate Forms of AD
- 2.2.1.1 Mild Cognitive Impairment
- 2.2.2 Moderate to Severe Forms of AD
- 2.3 AD Prevalence
- 2.3.1 Mild to Moderate AD Prevalence
- 2.3.1.1 Mild to Moderate AD Prevalence in US
- 2.3.1.2 Mild to Moderate AD Prevalence in Europe
- 2.3.1.3 Mild to Moderate AD Prevalence in Japan
- 2.3.2 Moderate to Severe AD Preva len ce
- 2.3.2.1 M od erate to Severe AD Prevalence in the US
- 2.3.2.2 M od erate to Severe AD Prevalence in Europe
- 2.3.2.3 M od erate to Severe AD Prevalence in Japan
- 2.4 Trea ted AD Patients
- 2.5 Average Sellin g Prices
- 2.6 Unmet Needs in Diagnosis and Trea tm en t of AD
- 2.6.1 Unmet Need s in the Diagnosis and Treatment of AD in the US
- 2.6.1.1 US Health Care Structure
- 2.6.1.2 Issues Specific to AD Patients
- 2.6.2 Unmet Needs in the Diagnosis and Treatment of AD in Europe
- 2.6.2.1 European Health Ca re Stru ctu re
- 2.6.2.2 Issues Specific to AD Patien ts
- 2.6.3 Unmet Need s in the Diagnosis and Treatment of AD in Japan
- 2.6.3.1 Japanese Health Care Structure
- 2.6.3.2 Issues Specific to AD Patients
3.0 MILD TO MODERATE AD MARKET
- 3.1 Market Overview
- 3.2 Mild to Moderate AD Drugs
- 3.2.1 Cognex
- 3.2.1.1 Cognex Clinical Results
- 3.2.1.2 Cognex Formulation , Dosing, and Compliance
- 3.2.2 Aricep t (M em a c)
- 3.2.2.1 Aricep t Clin ica l Results
- 3.2.2.2 Aricep t Formulation , Dosing and Compliance
- 3.2.3 Exelon (Prom eta x)
- 3.2.3.1 Exelon Clinical Results
- 3.2.3.2 Exelon Formulation , Dosing, and Compliance
- 3.2.4 Reminyl
- 3.2.4.1 Reminyl Clinica l Results
- 3.2.4.2 Reminyl Formulation , Dosing and Compliance
- 3.3 Market Analyses
- 3.3.1 US Market Forecast
- 3.3.2 European Market Forecast
- 3.3.3 Japanese Market Forecast
- 3.4 Competitive Analysis
4.0 MODERATE TO SEVERE AD MARKET
- 4.1 Market Overview
- 4.2 Moderate to Severe AD Drugs
- 4.2.1 Namenda
- 4.2.1.1 Namenda Clinical Results
- 4.2.1.2 Namenda Formulation , Dosing and Compliance
- 4.2.2 Axura
- 4.2.2.1 Axura Clinical Results
- 4.2.2.2 Axura Formulation , Dosing, and Compliance
- 4.2.3 Ebixa
- 4.2.3.1 Ebixa Clinical Results
- 4.2.3.2 Ebixa Formulation , Dosing, and Compliance
- 4.3 Market Analyses
- 4.3.1 US Market Forecast
- 4.3.2 European Market Forecast
- 4.3.3 Japanese Market Forecast
- 4.4 Competitive Analysis
5.0 R E SE AR CH AND D E V E LOPM E NT
- 5.1 AD Research Overview
- 5.1.1 ACh Modulators
- 5.1.1.1 ACh Modulators Drug Overview
- 5.1.1.2 ACh Modulators Drug Clinical Trial Data
- 5.1.1.3 ACh Modulators Drug Cand id ates by Clinical Stage
- 5.1.2 Neuroprotective and Neurotrophic Drugs
- 5.1.2.1 Neuroprotective and Neurotrophic Drug Overview
- 5.1.2.2 Neuroprotective and Neurotrophic Drug Clinical Trial Data
- 5.1.2.3 Neuroprotective and Neurotrophic Drug Candidates by Clinical
Stage
- 5.1.3 Beta-Am yloid Modulators
- 5.1.3.1 Beta-Am yloid Modulators Overview
- 5.1.3.2 Beta-Am yloid Modulators Clinical Trial Data
- 5.1.3.3 Beta -Am yloid M od u la tor Drug Cand id a tes b y Clin ica l
Stage
- 5.1.4 Beta-Secreta se Inhibitors
- 5.1.4.1 Beta-Secretase In h ib itor Drug Overview
- 5.1.4.2 Beta Secreta se (BACE ) In h ib itor Clinical Trial Data
- 5.1.4.3 Beta -Secretase (BACE ) In h ib itor Drug Candidates by
Clinical Sta ge
- 5.1.5 Other Drugs Under Development for AD
- 5.1.5.1 NMDA Recep tor An tagon ists
- 5.1.5.2 Phospholip id -Based Drugs
- 5.1.5.3 L-Typ e Calcium Channel Modulators
- 5.1.5.4 PD E -4 Compounds
- 5.1.5.5 Ampakine Compounds
- 5.1.5.6 Protein Deposition Inhibitors Overview
- 5.1.6 Application of Existin g Prod u cts to AD
- 5.1.6.1 Statins
- 5.1.6.2 Antioxidants
- 5.1.6.3 Hormones
- 5.1.6.4 Lithiu m
- 5.1.6.5 Rosiglitazone
- 5.1.6.6 Non steroidal Anti-Inflammatory Drugs (NSAID s)
- 5.1.6.7 Anti-Hypertensives
- 5.1.6.8 Rasagilen e
- 5.1.6.9 HT Agonists
- 5.1.6.10 Valproate
- 5.1.7 Innovative Approaches
- 5.1.7.1 Gene therapy
- 5.1.7.2 Vaccines
- 5.2 Companies Involved in AD Research
- 5.2.1 Eli Lilly
- 5.2.2 Pfizer/Eisai
- 5.2.3 San ofi-Aventis
- 5.2.4 Axonyx
- 5.2.5 Nymox
- 5.2.6 Prana Biotechnology
- 5.2.7 Neurochem
- 5.3 Discontinued Development Projects
APPENDIX A : MRG ACRONYMS AND INITIALISMS
| 
View Cart
